Gentium plunges on concerns by safety board over study
Gentium S.p.A. (Nasdaq:GENT) shares are plunging 27% after the biopharmaceutical company said a safety board had worries about the results of its late-stage trial of a treatment for severe veno-occlusive disease. The firm also received a downgrade by Rodman & Renshaw to “Market Perform” from “Outperform.”
In Friday afternoon trading, GENT shares are up 27.7%, or $2.05, to $5.35. For detailed price information and recent news stories about Gentium, click GENT.
About the Author
Reporter Will Atkinson is based in SmallCapInvestor.com's Washington, D.C. bureau.
Read More
(click a star)
Enter comment: